-
1.发明申请公开(公告)号：US20230019342A1
公开(公告)日：2023-01-19
申请号：US17850743
申请日：2022-06-27
Applicant: California Institute of Technology
Inventor： James R. Heath , Arundhati Nag , Samir Das , Joseph O. Varghese , Ryan K. Henning
IPC: G01N33/574 , C07K7/06 , C07K7/08 , C12Q1/48 , G01N33/58
Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
-
公开(公告)号：US20210025901A1
公开(公告)日：2021-01-28
申请号：US16827001
申请日：2020-03-23
Applicant: California Institute of Technology , Indi Molecular, Inc.
Inventor： James R. Heath , Heather Agnew , Blake Farrow , David Bunck , Jingxin Liang , Arundhati Nag , Samir Das , Bert Tsunyin Lai , Suresh Mark Pitram
Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
-
3.发明申请公开(公告)号：US20180364253A1
公开(公告)日：2018-12-20
申请号：US16010347
申请日：2018-06-15
Applicant: Indi Molecular, Inc. , California Institute of Technology
Inventor： Heather Agnew , Bert Tsunyin Lai , Suresh Mark Pitram , Blake Farrow , James R. Heath , David Bunck , Jingxin Liang , Arundhati Nag , Samir Das
Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
-
公开(公告)号：US11719705B2
公开(公告)日：2023-08-08
申请号：US16010347
申请日：2018-06-15
Applicant: Indi Molecular, Inc. , California Institute of Technology
Inventor： Heather Agnew , Bert Tsunyin Lai , Suresh Mark Pitram , Blake Farrow , James R. Heath , David Bunck , Jingxin Liang , Arundhati Nag , Samir Das
CPC classification number: G01N33/6869 , C07K7/06 , C07K14/54
Abstract: The present application provides stable peptide-based IL-17F and IL-17A capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
-
5.发明授权公开(公告)号：US11371994B2
公开(公告)日：2022-06-28
申请号：US14485243
申请日：2014-09-12
Applicant: California Institute of Technology
Inventor： James R. Heath , Arundhati Nag , Samir Das , Joseph O. Varghese , Ryan K. Henning
IPC: C07K7/06 , C12Q1/48 , G01N33/574 , C07K7/08 , G01N33/58
Abstract: The present application provides stable peptide-based Akt capture agents and methods of use as detection and diagnosis agents and in the treatment of diseases and disorders. The application further provides methods of manufacturing Akt capture agents using iterative on-bead in situ click chemistry.
-
Patent Agency Ranking
公开(公告)号：US20210101936A1
公开(公告)日：2021-04-08
申请号：US16908204
申请日：2020-06-22
Applicant: California Institute of Technology
Inventor： James R. Heath , Rosemary Dyane Rohde , Arundhati Nag , Samir Das , Aiko Umeda
IPC: C07K7/64 , A61K49/00 , C07K5/06 , C07K5/08 , A61K51/08 , C07K1/04 , C07K5/10 , C07K7/56 , C07K14/00 , G01N33/573 , G01N33/68
Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
-
公开(公告)号：US10598671B2
公开(公告)日：2020-03-24
申请号：US15211759
申请日：2016-07-15
Applicant: California Institute of Technology , Indi Molecular, Inc.
Inventor： James R. Heath , Heather Agnew , Blake Farrow , David Bunck , Jingxin Liang , Arundhati Nag , Samir Das , Bert Tsunyin Lai , Suresh Mark Pitram
Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.
-
公开(公告)号：US20160264627A1
公开(公告)日：2016-09-15
申请号：US15068528
申请日：2016-03-11
Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventor： Ryan K. Henning , Ashwin N. Ram , Samir Das , Arundhati Nag , James R. Heath
CPC classification number: C07K7/64 , A61K38/00 , C07K7/06 , C07K14/82 , G01N33/5748 , G01N2333/82 , G01N2333/914 , G01N2500/04
Abstract: Cyclic peptides represented by (Formula 1) selectively bind the oncoprotein K-Ras G12D in vitro and in cellulo, where Z1 and Z2 are each L-propargylglycine (Pra), azidoornithine (OrnN3), or L-azidolysine (Az4), and V1-V2-V3-V4-V5 is an amino acid variable region having a sequence selected from the group consisting of SEQ ID NOs: 1-20.
Abstract translation: 其中Z1和Z2分别为L-炔丙基甘氨酸（Pra），叠氮鸟氨酸（OrnN3）或L-叠氮基赖氨酸（Az4）和V1-V2-V3-V4-V5（纤维素酶），在体外和纤维素中选择性结合癌蛋白K-Ras G12D 是具有选自SEQ ID NO：1-20的序列的氨基酸可变区。
-
公开(公告)号：US11365219B2
公开(公告)日：2022-06-21
申请号：US16908204
申请日：2020-06-22
Applicant: California Institute of Technology
Inventor： James R. Heath , Rosemary Dyane Rohde , Arundhati Nag , Samir Das , Aiko Umeda
IPC: C07K7/64 , A61K49/00 , C07K5/06 , C07K5/08 , A61K51/08 , C07K5/10 , C07K1/04 , C07K7/56 , C07K14/00 , G01N33/573 , G01N33/68
Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
-
公开(公告)号：US11168115B2
公开(公告)日：2021-11-09
申请号：US14310201
申请日：2014-06-20
Applicant: California Institute of Technology
Inventor： James R. Heath , Rosemary Dyane Rohde , Arundhati Nag , Samir Das , Aiko Umeda
IPC: C07K7/64 , A61K51/08 , A61K49/00 , C07K5/06 , C07K5/08 , C07K1/04 , C07K5/10 , C07K7/56 , C07K14/00 , G01N33/573 , G01N33/68
Abstract: Peptides having activity as protein binding agents are disclosed. The peptides have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R, R1, L1, L2, G, M, Y1 Y2 and SEQ are as defined herein. Methods associated with preparation and use of such peptides, as well as pharmaceutical compositions comprising such peptides, are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.024 seconds)
